Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: Results from cancer and leukemia group B study 19805

Clinical Cancer Research

Volumn 11, Issue 11, 2005, Pages 4176-4181

  Byrd, John C ^a   Peterson, Bercedis L ^b   Gabrilove, Janice ^c   Odenike, Olatoyosi M ^d   Grever, Michael R ^a   Rai, Kanti ^e   Larson, Richard A ^d  

^a OHIO STATE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MOUNT SINAI HOSPITAL   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALLOPURINOL; COLESTIPOL; FLAVOPIRIDOL; FLUDARABINE; LOPERAMIDE; PROTEIN P53; RITUXIMAB;

ADULT; AGED; ANEMIA; APOPTOSIS; ARTICLE; BLOOD TOXICITY; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE ACTIVITY; DISEASE COURSE; DRUG ACTIVITY; DYSPNEA; FATIGUE; GRANULOCYTOPENIA; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; IN VITRO STUDY; INFECTION; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEPHROTOXICITY; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN FUNCTION; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLAVONOIDS; HUMANS; INFUSION PUMPS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUTROPENIA; PIPERIDINES; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 20344368831     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2276     Document Type: Article

References (28)

1. Kitada S, Zapata JM, Andreeff M, et al. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000;96:393-7.
2. Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998;92:3804-16.
3. Konig A, Schwartz GK, Mohammad RM, et al. The novel cyclin-dependent kinase inhibitor flavopiridol down-regulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 1997;90:4307-12.
4. Thomas JP, Tutsch KD, Cleary JF, et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002;50:465-72.
5. Senderowicz AM, Headlee D, Stinson SF, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998;16:2986-99.
6. Schwartz GK, O'Reilly E, llson D, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002;20:2157-70.
7. Tan AR, Headlee D, Messmann R, et al. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 2002;20:4074-82.
8. Messmann RA, Ullmann CD, Lahusen T, et al. Flavo-piridol-related proinflammatory syndrome is associated with induction of interleukin-6. Clin Cancer Res 2003;9:562-70.
9. Aklilu M, Kindler HL, Donehower RC, et al. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 2003;14:1270-3.
10. Schwartz GK, Ilson D, Saltz L, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001;19:1985-92.
11. Stadler WM, Vogelzang NJ, Amato R, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago phase II consortium study. J Clin Oncol 2000;18:371-5.
12. Shapiro GI, Supko JG, Patterson A, et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 2001;7:1590-9.
13. Lin TS, Howard OM, Neuberg DS, et al. Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leuk Lymphoma 2002;43:793-7.
14. Kouroukis CT, Belch A, Crump M, et al. Flavopiridolin untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2003;21:1740-5.
15. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7.
16. Kaplan EL, Meter P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;43:457-81.
17. Peto RPM, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient II. Analysis and examples. Br J Cancer 1977;35:1-39.
18. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61.
19. Rudek MA, Bauer KS Jr, Lush RM III, et al. Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. Ann Pharmacother 2003;37:1369-74.
20. Flinn IW, Byrd JC, Barlett N, et al. Flavopiridol administered as a 24-hour continous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res. In press 2005.
21. Shinn C, Larsen D, Suarez JR, et al. Flavopiridol sensitivity of chronic lymphocytic leukemia (CLL) cells in vitro varies based upon species specific drug protein binding. Blood 2000;96:294b.
22. Innocenti F, Stadler WM, Iyer L, et al. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res 2000;6:3400-5.
23. Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 1997;57:3375-80.
24. Matranga CB, Shapiro GI. Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase. Cancer Res 2002;62:1707-17.
25. Schwartz GK, Farsi K, Maslak P, et al. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin Cancer Res 1997;3:1467-72.
26. Yu C, Krystal G, Dent P, et al. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin Cancer Res 2002;8:2976-84.
27. Dai Y, Rahmani M, Grant S. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process. Oncogene 2003;22:7108-22.
28. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered as a pharmacologically-derived schedule demonstrates marked clinical activity in refractory, genetically high risk, chronic lymphocytic leukemia (CLL). Blood 2004;104:476a.